Clinical Trials
9
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:6
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Not Applicable
1 (12.5%)Phase 3
1 (12.5%)Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Not Applicable
Not yet recruiting
- Conditions
- AL Amyloidosis
- Interventions
- Biological: Eque-cel CAR-T Therapy
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT07055724
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Recruiting
- Conditions
- Multiple Myeloma
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 1500
- Registration Number
- NCT07028970
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳People's Hospital of Peking Universit, Beijing, China
🇨🇳Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies
Phase 1
Not yet recruiting
- Conditions
- Large B-cell Lymphoma
- Interventions
- Genetic: UB-VV400
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06743503
A Phase III Study of Eque-cel in Subjects with Len-refractory RRMM (FUMANBA-03)
Phase 3
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing GoBoard Boren Hospital, Beijing, China
🇨🇳Fu Xing Hospital, Capital Medical University, Beijing, China
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05759793
- Locations
- 🇨🇳
Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Prev
- 1
- 2
- Next
News
No news found